Continuing their decline from last week, European equities traded in the US as American depositary receipts were sharply lower late Monday morning, falling 1.73% to 1,257.11 on the S&P Europe Select ADR Index.
From continental Europe, the gainers were led by furniture maker Natuzzi (NTZ) and biopharmaceutical company DBV Technologies (DBVT), which climbed 6.5% and 5.7%, respectively. They were followed by pharmaceutical company Novo Nordisk (NVO) and biopharmaceutical company Grifols (GRFS), which increased 1.7% and 0.7%, respectively.
The decliners from continental Europe were led by oil and gas company Eni (E) and pharmaceutical company Ascendis Pharma (ASND), which dropped 5.6% and 3.8%, respectively. They were followed by biotech firm Evaxion Biotech (EVAX) and consumer goods company Unilever (UL), which were down 3.7% each.
From the UK and Ireland, the gainers were led by biopharmaceutical company Akari Therapeutics (AKTX) and software firm Endava (DAVA), which rose 6.5% and 4.9%, respectively. They were followed by mining company BHP Group (BHP) and pharmaceutical company Silence Therapeutics (SLN), which were up 1.9% and 1.2%, respectively.
The decliners from the UK and Ireland were led by biotech firm Trinity Biotech (TRIB) and pharmaceutical company AstraZeneca (AZN), which lost 6.2% and 5.4%, respectively. They were followed by pharmaceutical companies GSK (GSK) and biopharmaceutical company Biodexa Pharmaceuticals (BDRX), which fell 5.3% and 5.2%, respectively.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。